Innoviva (INVA) Total Non-Current Liabilities (2013 - 2026)
Innoviva's (INVA) quarterly Total Non-Current Liabilities came in at -$68.9 million in Q1 2026, down 494.3% YoY from $17.5 million in Q1 2025, and down 21.28% on a QoQ basis from -$56.8 million in Q4 2025.
Analysis
Innoviva (INVA) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Innoviva (INVA) has 14 years of Total Non-Current Liabilities data on file, last reported at -$68.9 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 494.3% year-over-year to -$68.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.9 million (down 494.3% YoY) and the FY2025 annual result came in at -$56.8 million, up 11.33% from the prior year.
- Total Non-Current Liabilities eased to -$68.9 million in Q1 2026, from -$56.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $103.3 million in Q3 2023 to a low of -$71.5 million in Q2 2024.
- A 5-year average of -$11.1 million and a median of -$55.0 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 20050.0% — and 2026, when it sank 494.3%.
- Tracing INVA's Total Non-Current Liabilities over 5 years: stood at $40.3 million in 2022, then jumped by 156.24% to $103.3 million in 2023, then tumbled by 162.05% to -$64.1 million in 2024, then advanced by 11.33% to -$56.8 million in 2025, then dropped by 21.28% to -$68.9 million in 2026.
- The last three Total Non-Current Liabilities figures came in at -$68.9 million (Q1 2026), -$56.8 million (Q4 2025), and $45.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | -67.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -67.18 Mn |
| Mar 31, 2026 | -68.90 Mn |
| Dec 31, 2025 | -65.99 Mn |
| Sep 30, 2025 | 45.15 Mn |
| Jun 30, 2025 | -59.92 Mn |
| Mar 31, 2025 | -61.81 Mn |
| Dec 31, 2024 | -64.08 Mn |
| Sep 30, 2024 | 31.01 Mn |
| Jun 30, 2024 | -71.47 Mn |
| Mar 31, 2024 | -69.89 Mn |
| Dec 31, 2023 | 103.26 Mn |
| Sep 30, 2023 | 103.26 Mn |
| Jun 30, 2023 | -67.88 Mn |
| Mar 31, 2023 | -66.03 Mn |
| Dec 31, 2022 | 40.30 Mn |
| Sep 30, 2022 | 40.30 Mn |
| Dec 31, 2021 | 200,000.00 |
| Sep 30, 2021 | 13.66 Mn |
| Jun 30, 2021 | 395.36 Mn |
| Mar 31, 2021 | 391.53 Mn |